Lisa M Kaminskas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9489581/publications.pdf

Version: 2024-02-01

80 papers	4,191 citations	116194 36 h-index	129628 63 g-index
80 all docs	80 docs citations	80 times ranked	5690 citing authors

#	Article	IF	Citations
1	Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. Acta Biomaterialia, 2022, 142, 298-307.	4.1	7
2	Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. Nanomedicine, 2021, 16, 275-292.	1.7	5
3	Recent advances in nano/microparticle-based oral vaccines. Journal of Pharmaceutical Investigation, 2021, 51, 425-438.	2.7	17
4	Monocytes Do Not Contribute to Sex Differences Seen in the Pharmacokinetics of Pegylated Liposomal Doxorubicin. Journal of Pharmaceutical Sciences, 2021, 110, 3099-3101.	1.6	2
5	The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction. Journal of Controlled Release, 2021, 337, 71-80.	4.8	4
6	Poly(HPMA-co-NIPAM) copolymer as an alternative to polyethylene glycol-based pharmacokinetic modulation of therapeutic proteins. International Journal of Pharmaceutics, 2021, 608, 121075.	2.6	7
7	Nitroxide-functional PEGylated nanostars arrest cellular oxidative stress and exhibit preferential accumulation in co-cultured breast cancer cells. Journal of Materials Chemistry B, 2021, 9, 7805-7820.	2.9	3
8	Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Pharmaceutical Research, 2020, 37, 3.	1.7	23
9	The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 30, 102291.	1.7	22
10	Lymph-directed immunotherapy â€“ Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135.	6.6	18
11	Trisulfide-Bearing PEG Brush Polymers Donate Hydrogen Sulfide and Ameliorate Cellular Oxidative Stress. Biomacromolecules, 2020, 21, 5292-5305.	2.6	8
12	The Impact of Polymer Size and Cleavability on the Intravenous Pharmacokinetics of PEG-Based Hyperbranched Polymers in Rats. Nanomaterials, 2020, 10, 2452.	1.9	8
13	Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure. Pharmaceutical Research, 2020, 37, 224.	1.7	4
14	Drug formulation and nanomedicine approaches to targeting lymphatic cancer metastases. Nanomedicine, 2019, 14, 1605-1621.	1.7	15
15	dendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction. Scientific Reports, 2019, 9, 15465.	1.6	32
16	Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats. Journal of Controlled Release, 2019, 307, 32-43.	4.8	26
17	A 30â€¯kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 137, 218-226.	2.0	9
18	Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?. Drug Development and Industrial Pharmacy, 2019, 45, 882-894.	0.9	37

#	Article	IF	Citations
19	Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration. Journal of Liposome Research, 2019, 29, 1-9.	1.5	39
20	The Applications of 3D Printing in Pulmonary Drug Delivery and Treatment of Respiratory Disorders. Current Pharmaceutical Design, 2019, 24, 5072-5080.	0.9	5
21	Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. Journal of Controlled Release, 2018, 272, 17-28.	4.8	16
22	A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 1-12.	2.0	42
23	Linker chemistry dictates the delivery of a phototoxic organometallic rhenium(<scp>i</scp>) complex to human cervical cancer cells from core crosslinked star polymer nanoparticles. Journal of Materials Chemistry B, 2018, 6, 7805-7810.	2.9	9
24	Suggested Procedures for the Reproducible Synthesis of Poly(d,l-lactideco-glycolide) Nanoparticles Using the Emulsification Solvent Diffusion Platform. Current Nanoscience, 2018, 14, 448-453.	0.7	25
25	Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. Journal of Pharmaceutical Sciences, 2018, 107, 2509-2513.	1.6	13
26	Prediction and Optimization of Pharmacokinetic and Toxicity Properties of the Ligand. Methods in Molecular Biology, 2018, 1762, 271-284.	0.4	42
27	Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. Molecular Pharmaceutics, 2018, 15, 4568-4576.	2.3	41
28	Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly. Biomacromolecules, 2017, 18, 3963-3970.	2.6	87
29	Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 408-418.	2.0	28
30	An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. Biomacromolecules, 2017, 18, 2866-2875.	2.6	15
31	Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2485-2494.	1.7	22
32	Polymer-drug conjugates as inhalable drug delivery systems: A review. Current Opinion in Colloid and Interface Science, 2017, 31, 18-29.	3.4	66
33	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. Molecular Pharmaceutics, 2016, 13, 1904-1914.	2.3	30
34	A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. Pharmaceutical Research, 2016, 33, 510-525.	1.7	22
35	Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1703-1724.	1.7	67
36	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fabâ€² Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. Molecular Pharmaceutics, 2016, 13, 1229-1241.	2.3	25

#	Article	IF	Citations
37	The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. Journal of Pharmaceutical Sciences, 2016, 105, 293-300.	1.6	17
38	Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state properties for glassy stabilisation. Powder Technology, 2016, 287, 248-255.	2.1	20
39	Practical Lessons in Murine Thoracic Lymph Duct Cannulations: Observations in Female and Male Mice Across Four Different Strains That Impact on â€œCannulatabilityâ€• Journal of Pharmaceutical Sciences, 2015, 104, 1207-1209.	1.6	3
40	Optimal PEGylation can Improve the Exposure of Interferon in the Lungs Following Pulmonary Administration. Journal of Pharmaceutical Sciences, 2015, 104, 1421-1430.	1.6	24
41	PEGylated Interferon Displays Differences in Plasma Clearance and Bioavailability Between Male and Female Mice and Between Female Immunocompetent C57Bl/6J and Athymic Nude Mice. Journal of Pharmaceutical Sciences, 2015, 104, 1848-1855.	1.6	6
42	Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats. Molecular Pharmaceutics, 2015, 12, 432-443.	2.3	51
43	PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration. Molecular Pharmaceutics, 2015, 12, 794-809.	2.3	34
44	Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 361-371.	0.7	42
45	From sewer to saviour â€" targeting the lymphatic system to promote drug exposure and activity. Nature Reviews Drug Discovery, 2015, 14, 781-803.	21.5	479
46	Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2099-2108.	1.7	17
47	Dendrimers for Biomedical Applications. Frontiers in Nanobiomedical Research, 2014, , 279-328.	0.1	0
48	Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. Journal of Controlled Release, 2014, 183, 18-26.	4.8	158
49	Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. Journal of Controlled Release, 2014, 193, 241-256.	4.8	107
50	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. Molecular Pharmaceutics, 2014, 11, 496-504.	2.3	49
51	Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent. Molecular Pharmaceutics, 2013, 10, 2986-2995.	2.3	93
52	Designing a Multicomponent Spray-Dried Formulation Platform for Pulmonary Delivery of Biomacromolecules: The Effect of Polymers on the Formation of an Amorphous Matrix for Glassy State Stabilization of Biomacromolecules. Drying Technology, 2013, 31, 1451-1458.	1.7	20
53	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 2013, 172, 128-136.	4.8	74
54	PEGylation of interferon Î±2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. Journal of Controlled Release, 2013, 168, 200-208.	4.8	70

#	Article	IF	Citations
55	The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 234-243.	2.0	115
56	Chaperone Heat Shock Protein 90 Mobilization and Hydralazine Cytoprotection against Acrolein-Induced Carbonyl Stress. Molecular Pharmacology, 2012, 82, 876-886.	1.0	14
57	Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models. Molecular Pharmaceutics, 2012, 9, 422-432.	2.3	63
58	Association of Chemotherapeutic Drugs with Dendrimer Nanocarriers: An Assessment of the Merits of Covalent Conjugation Compared to Noncovalent Encapsulation. Molecular Pharmaceutics, 2012, 9, 355-373.	2.3	125
59	A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 103-111.	1.7	152
60	Capping Methotrexate Î±-Carboxyl Groups Enhances Systemic Exposure and Retains the Cytotoxicity of Drug Conjugated PEGylated Polylysine Dendrimers. Molecular Pharmaceutics, 2011, 8, 338-349.	2.3	61
61	Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine, 2011, 6, 1063-1084.	1.7	166
62	New developments in dry powder pulmonary vaccine delivery. Trends in Biotechnology, 2011, 29, 191-198.	4.9	109
63	Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. Journal of Controlled Release, 2011, 152, 241-248.	4.8	121
64	Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach. International Journal of Pharmaceutics, 2011, 421, 220-229.	2.6	51
65	Targeting the lymphatics using dendritic polymers (dendrimers). Advanced Drug Delivery Reviews, 2011, 63, 890-900.	6.6	108
66	Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. Journal of Pharmaceutical Sciences, 2011, 100, 5069-5077.	1.6	67
67	Nanosized Drug Delivery Vectors and the Reticuloendothelial System. Fundamental Biomedical Technologies, 2011, , 155-178.	0.2	7
68	PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. Journal of Controlled Release, 2009, 140, 108-116.	4.8	130
69	Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-<scp>l</scp>-lysine Dendrimers. Molecular Pharmaceutics, 2009, 6, 1190-1204.	2.3	130
70	The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly <scp>l</scp>-Lysine Dendrimers. Molecular Pharmaceutics, 2008, 5, 449-463.	2.3	165
71	Impact of Surface Derivatization of Poly-<scp>l</scp>-lysine Dendrimers with Anionic Arylsulfonate or Succinate Groups on Intravenous Pharmacokinetics and Disposition. Molecular Pharmaceutics, 2007, 4, 949-961.	2.3	50
72	Michael addition of acrolein to lysinyl and N-terminal residues of a model peptide: targets for cytoprotective hydrazino drugs. Rapid Communications in Mass Spectrometry, 2007, 21, 1155-1164.	0.7	15

#	Article	IF	Citations
73	Cationic Poly-l-lysine Dendrimers:â€‰ Pharmacokinetics, Biodistribution, and Evidence for Metabolism and Bioresorption after Intravenous Administration to Rats. Molecular Pharmaceutics, 2006, 3, 614-627.	2.3	149
74	Differences in Lysine Adduction by Acrolein and Methyl Vinyl Ketone:â€‰ Implications for Cytotoxicity in Cultured Hepatocytes. Chemical Research in Toxicology, 2005, 18, 1627-1633.	1.7	28
75	Protein Adduct-Trapping by Hydrazinophthalazine Drugs: Mechanisms of Cytoprotection Against Acrolein-Mediated Toxicity. Molecular Pharmacology, 2004, 65, 655-664.	1.0	55
76	Strong Protein Adduct Trapping Accompanies Abolition of Acrolein-Mediated Hepatotoxicity by Hydralazine in Mice. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1003-1010.	1.3	64
77	Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. Organic and Biomolecular Chemistry, 2004, 2, 2578.	1.5	47
78	The contribution of the metabolite p -hydroxyamphetamine to the central actions of p -methoxyamphetamine. Psychopharmacology, 2002, 160, 155-160.	1.5	15
79	Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology, 2002, 181-182, 229-236.	2.0	78
80	Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep. Frontiers in Pharmacology, 0, 13, .	1.6	1